Mitoquinol (MitoQ)
SupplementThe medical score (52) is slightly below the community score (62), as clinical studies [s9] showed no significant effect in key indications (Parkinson's disease, hepatitis C) and the total sample size across all RCTs is small [s7]. Community users, however, frequently report positive subjective effects on energy and recovery [c1, c2], which is typical for antioxidant supplements where placebo effects and selection bias play a role.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
MitoQ is a mitochondria-targeted CoQ10 analogue with its strongest clinical evidence in vascular function and exercise-induced oxidative stress — both from small RCTs totalling under 500 subjects. It showed no significant effect in Parkinson's disease or hepatitis C trials. Community users report subjective energy and recovery benefits, but consistently flag the high cost relative to standard ubiquinol. Without a specific vascular or athletic rationale, conventional ubiquinol likely offers comparable value at a fraction of the price.
Description
Mitoquinol (MitoQ) is a synthetic CoQ10 analogue that selectively accumulates in mitochondria and reduces oxidative stress therein [s1, s2].
Mitoquinol mesylate (MitoQ) is a synthetic derivative of coenzyme Q10 (CoQ10), developed in New Zealand in the late 1990s [s3]. Unlike conventional CoQ10, MitoQ is conjugated to a positively charged triphenylphosphonium (TPP+) group. This charge causes the molecule to be selectively taken up into mitochondria driven by the strongly negative membrane potential of the inner mitochondrial membrane – with an accumulation several hundred times greater than that of unmodified CoQ10 [s1, s3]. MitoQ demonstrates markedly improved bioavailability in blood compared to conventional CoQ10 and is water-soluble, facilitating absorption in the small intestine [s3, s4]. In clinical studies, MitoQ has been investigated primarily in the following areas: - Vascular function and blood pressure in older adults [s5, s6] - Athletic performance and exercise-induced oxidative damage [s7, s8] - Parkinson's disease (Phase 2 trial with no significant effect on disease progression) [s9] - Chronic hepatitis C (Phase 2 trial) [s9] - Aging biomarkers and oxidative stress (systematic review) [s10] Overall, the clinical evidence base for MitoQ remains limited. Most human RCTs have small sample sizes (n < 100). Results are promising in certain areas (vascular function, reduction of oxidative stress markers during exercise), but disappointing in others (Parkinson's disease, hepatitis C). Further adequately powered RCTs are necessary before robust clinical recommendations can be made [s7, s10].
Legal Status (DE)
{'eu_novel_food': {'status': 'not_verified', 'note_de': 'A search on ec.europa.eu returned no result for mitoquinone mesylate (MitoQ) in the EU Novel Food Catalogue (Regulation (EU) 2015/2283). A definitive classification (approved / not approved / application submitted / not listed) could not be confirmed. Manual review of the EU Novel Food Catalogue at https://ec.europa.eu/food/safety/novel-food/catalogue is recommended.'}}
Mechanism of Action
{'Nrf2_note': 'Nrf2/ARE activation by MitoQ has so far only been demonstrated preclinically (intestinal epithelial cells, s12). A human in vivo study or clinical trial confirming this mechanism in humans could not be identified in the literature search (up to 2025). The mechanism is therefore still considered preclinical.'}
Dosing
Allgemeine antioxidative Unterstützung / Gefäßfunktion
- Dose
- 10 mg mitoquinol mesylate
- Frequency
- 1× täglich
- Route
- oral
- Duration
- mindestens 4–12 Wochen
- Timing
- Morning, fasted or with a small meal
- With food
- optional
Sportliche Leistung / Reduktion trainingsinduzierten oxidativen Schadens
- Dose
- 20 mg mitoquinol mesylate
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 3–6 Wochen
- Timing
- Morning
- With food
- optional
Ältere Erwachsene (Altersstudie)
- Dose
- 20 mg mitoquinol mesylate
- Frequency
- 1× täglich
- Route
- oral
- Duration
- 12 Wochen
- Timing
- Morning
- With food
- optional
In clinical studies, doses of up to 80 mg/day have been used over short periods without serious adverse events [s9]. The manufacturer-recommended daily dose is 10–20 mg. Higher doses have only been tested in early-phase studies; no official upper limit has been established by regulatory authorities (BfR, EFSA) [s11].
MitoQ is water-soluble and can be taken without a high-fat meal – an advantage over conventional CoQ10 [s3, s4]. The 10 mg dose corresponds to the standard commercially available product.
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Magenbeschwerden) Mild gastrointestinal side effects at higher doses (80 mg) were reported in phase 2 studies [s9]. Rare at standard doses (10–20 mg). | gelegentlich | leicht |
| Kopfschmerzen Occasionally reported in clinical studies without clear causal attribution [s9]. | selten | leicht |
| Erhöhte Leberwerte (transaminase elevation) In the hepatitis C phase 2 study with higher doses (40–80 mg), elevated transaminases were observed in individual subjects [s9]. No evidence of hepatotoxic effects at standard doses (10–20 mg). | selten | moderat |
| Subjektiv fehlende Wirkung im Vergleich zu Ubichinol Community reports describe that some users perceive no benefit from MitoQ over conventional CoQ10 (ubiquinol) [c1]. | gelegentlich | leicht |
Contraindications
Elevated transaminases have been observed in patients with severe liver disease in higher-dose studies [s9]. Caution advised; medical monitoring of liver values recommended.
CoQ10 analogues may theoretically interfere with the effect of vitamin K antagonists such as warfarin. No direct interaction study for MitoQ is available; caution is warranted and INR monitoring is recommended due to structural similarity to CoQ10 [s14].
No human safety data available for pregnancy and lactation. Use not recommended.
Interactions
Synergistic
Mitoquinol (MitoQ) is a mitochondrially targeted ubiquinol analogue that is selectively concentrated in the inner mitochondrial membrane via a triphenylphosphonium group, while CoQ10-ubiquinol replenishes the systemic and membranous redox pool. Combined use may produce a synergistic antioxidant effect by more potently suppressing both intramitochondrial oxidative stress and cytosolic lipid peroxidation.
No peer-reviewed animal study on cardioprotection (ischemia-reperfusion) with MitoQ + alpha-lipoic acid in aged rat hearts found in the search. Field remains empty pending verification.
ALCAR transports acetyl groups into mitochondria and provides acetyl-CoA for energy production. Combined with MitoQ, which reduces mitochondrial oxidative stress, synergistic effects on energy metabolism and mitochondrial function are mechanistically plausible.
MitoQ is used by the manufacturer itself in NAD+-combination formulas, as NMN raises NAD+ levels thereby activating sirtuins, while MitoQ protects mitochondria at the ROS level. According to manufacturer claims, both compounds act synergistically on cellular energy and repair processes.
In a clinical study, both MitoQ and CoQ10/ubiquinol suppressed mitochondrial H₂O₂ levels during leak respiration in skeletal muscle cells of middle-aged men. Effects were comparable; however, bioavailability within mitochondria differs.
MitoQ and astaxanthin both belong to the group of lipid-soluble, mitochondria-penetrating antioxidants. A mechanistic review categorizes both as complementary membrane antioxidants with similar target structures in the mitochondrial membrane.
MitoQ is marketed by the manufacturer in combination with NAD+ boosters and resveratrol, as resveratrol directly activates sirtuins and MitoQ protects mitochondria from oxidative stress, enabling NAD+-dependent processes to operate more efficiently. The combination is mechanistically plausible but has not yet been evaluated in clinical RCTs.
Berberine activates AMPK through mild inhibition of mitochondrial complex I, thereby increasing the AMP/ATP ratio. MitoQ simultaneously protects mitochondria from the resulting oxidative stress. These complementary mechanisms of action may act synergistically, but have not yet been clinically substantiated.
Caution
No specific PubMed entry confirming MitoQ-mediated complex I inhibition found in the available search results. Field remains empty pending verification.
Studies
Tier B — Moderate Evidence
Community Evidence
Top reported benefits
- Subjectively improved energy and recovery after exercise
- Perceived reduction in fatigue
- Positive experiences in fluoroquinolone-induced damage (r/floxies)
- General well-being and anti-aging motivation
Top reported issues
- High cost relative to subjectively perceived benefit
- No discernible difference from conventional ubiquinol in some users
- Uncertainty about optimal dosing
Several community users report that MitoQ is more expensive than conventional CoQ10/ubiquinol without a clear subjective advantage [c1]. Data on long-term safety at high doses is limited [s9]. In German-language forums, MitoQ is discussed primarily as a supplementary agent for fluoroquinolone-associated adverse effects – an indication without a clinical evidence base [c2].
Scientific Sources
- Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: A study protocol
Horrigan LA, Dobson GP, Letson HL, et al. (2022). Frontiers in PhysiologyBDOI - The Effect of MitoQ on Aging-Related Biomarkers: A Systematic Review and Meta-Analysis
Braakhuis AJ, Jeng W, Liu Y, et al. (2018). Oxidative Medicine and Cellular LongevityADOI - Directive 2002/46/EC of the European Parliament and of the Council on the approximation of the laws of the Member States relating to food supplements
European Parliament, Council of the European Union (2002). Official Journal of the European CommunitiesALink - The mitochondrially targeted antioxidant MitoQ protects the intestinal barrier by ameliorating mitochondrial DNA damage via the Nrf2/ARE signaling pathway
Xiao L, Xu X, Zhang F, et al. (2018). Cell Death & DiseaseCDOI - MitoQ inhibits hepatic stellate cell activation and liver fibrosis by enhancing PINK1/parkin-mediated mitophagy
Dou SY, Zhang JN, Xie XL, et al. (2021). Open MedicineCDOI - Warfarin Drug Interactions - StatPearls
Ageno W, Gallus AS, Wittkowsky A, et al. (2023). NCBI Bookshelf / StatPearlsBLink - MitoQ and CoQ10 supplementation mildly suppresses skeletal muscle mitochondrial hydrogen peroxide levels without impacting mitochondrial function in middle-aged men
Pham T, MacRae CL, Broome SC, D'Souza RF, Narang R, Wang HW, Mitchell CJ, Merry TL (2020). European Journal of Applied PhysiologyAPMID:32458156DOI - Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress
Murray KO, Ludwig KR, Darvish S, Coppock ME, Seals DR, Rossman MJ (2023). American Journal of Physiology – Heart and Circulatory PhysiologyAPMID:37326998DOI - Acute effects of MitoQ on vascular endothelial function are influenced by cardiorespiratory fitness and baseline FMD in middle-aged and older adults
Carlini NA, Harber MP, Fleenor BS (2024). Journal of PhysiologyBPMID:38568933DOI - How does MitoQ work – the mechanism of action
MitoQ Limited (2023). MitoQ Blog (manufacturer)DLink - Mitoquinone mesylate
Wikipedia contributors (2024). WikipediaDLink - Transport and metabolism of MitoQ10, a mitochondria-targeted antioxidant, in Caco-2 cell monolayers
Porteous CM, Menon DK, Aigbirhio FI, et al. (2007). Journal of Pharmacy and PharmacologyCPMID:17430633 - Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults
Rossman MJ, Santos-Parker JR, Steward CAC, et al. (2018). HypertensionAPMID:29610356DOI - Frontiers | Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans: A study protocol (NCT04851288)
Horrigan LA, Dobson GP, Letson HL, et al. (2022). Frontiers in PhysiologyBDOI - Effects of Mitoquinone (MitoQ) Supplementation on Aerobic Exercise Performance and Oxidative Damage: A Systematic Review and Meta-analysis
Gonzalo-Skok O, Casuso RA (2024). Sports Medicine - OpenAPMID:38981985DOI - Moderate Endurance Training and MitoQ Improve Cardiovascular Function, Oxidative Stress, and Inflammation in Hypertensive Individuals: The Role of miR-21 and miR-222: A Randomized, Double-Blind, Clinical Trial
Park SY, Ives SJ, Gifford JR, et al. (2022). PMC / Frontiers in Cardiovascular MedicineALink - Antipodean Pharmaceuticals, Inc. Announces Results of Phase 2 Study of Lead Compound MitoQ (PROTECT trial – Parkinson's; Hepatitis C Phase 2)
Antipodean Pharmaceuticals Inc. (2008). BioSpace / ScienceDirect OverviewBLink - The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients
Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RAJ, Murphy MP (2010). Liver InternationalAPMID:20492507DOI - A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease
Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O'Sullivan JD, Fung V, Smith RAJ, Murphy MP, Taylor KM; Protect Study Group (2010). Movement DisordersAPMID:20568096DOI
Community Sources
Storage
Unopened
Store dry at room temperature (15–25 °C), protected from light.
Opened
Keep tightly closed; avoid moisture. Consume before the best-before date.
Notes
MitoQ capsules are light-sensitive; use original packaging.